In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Alkermes (NASDAQ: ALKS). The company’s shares closed yesterday at $41.91, close to its 52-week low of $39.54.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.6% and a 38.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Jounce Therapeutics Inc, and Vertex Pharmaceuticals.
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $52.71, a 25.8% upside from current levels. In a report issued on June 22, B.Riley FBR also maintained a Buy rating on the stock with a $60 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.22 and a one-year low of $39.54. Currently, Alkermes has an average volume of 1.09M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. It operates through the following geographical segments: U.S., Ireland, Rest of the World, and Other.
